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SUMMARY
Buruli ulcers (BU) is a disease caused by infection with Mycobacterium ulcerans. It is 
one of the most neglected but treatable tropical diseases. Cases of Buruli ulcers are 
extremely rare in Gulu District. It is because of this reason that we report a case of a 
25 year old male patient who presented with Buruli ulcers on the right thigh. 
INTRODUCTION
Buruli ulcers (BU), is a disease caused by infection 
with Mycobacterium ulcerans (1). It is one of the most 
neglected but treatable tropical diseases (1,2). The 
causative organism is from the family of bacteria 
which causes tuberculosis and leprosy but Buruli 
ulcer has received least attention than these other two 
diseases (1,2). Infection leads to extensive destruction 
of skin and soft tissues with the formation of large 
ulcers usually on the legs or arms. Patients who are 
not treated early often suffer long-term functional 
disability such as restriction of joint movement as 
well as the obvious cosmetic problems (1-5). Early 
diagnosis and treatment are vital in preventing such 
disabilities (6-9). Buruli ulcer has been reported in over 
30 countries mainly in the tropical and sub-tropical 
climates but it may also occur in some countries where 
it has not yet been recognised. Limited knowledge of 
the disease, its focal distribution and its occurrence 
mainly amongst poor rural communities contribute to 
low reporting of cases (9, 10). In 1897, Sir Albert Cook, 
a British physician working at the Mengo Hospital 
in Kampala, Uganda, described skin ulcers that were 
consistent with Buruli ulcer (BU)(1). 
 In 1948, Professor Peter MacCallum and his 
colleagues in Australia provided a detailed description 
of a similar disease among six patients from the 
Bairnsdale area near Melbourne (9,10). They were 
the first scientists to isolate the causative organism, 
Mycobacterium ulcerans (9). In Southern Australia, the 
disease is still referred to as the Bairnsdale ulcer (9). 
In the 1960s, many cases occurred in Buruli County 
(now called Nakasongola District) in Uganda, giving 
rise to the most widely used name for the disease – 
Buruli ulcer (8,9). Since 1980, the disease has emerged 
rapidly in several parts of the world, particularly in 
West Africa (9). Given the increasing geographical 
spread, severe consequences and limited knowledge 
of the disease, there is need for improved surveillance 
methods and control.
 We discuss in this paper the characteristic clinical 
features, investigations, management and control of 
Buruli ulcer.
CASE REPORT
A 25 year old male peasant farmer from Koch Goma 
Sub County in Gulu District presented to Gulu 
Hospital Casualty unit during the night of February 
2006 with a one month’s history of an ulcer in the 
right thigh. He had moved to several health facilities 
for treatment but without any improvement. He 
gave a history that the ulcer started with a small 
itchy nodule at the upper right thigh. Because he 
was scratching on the nodule, three weeks later it 
developed into an ulcer. He reported to have been 
cultivating crops in the nearby the swamps. He also 
admitted that very often he made sleeping mat from 
papyrus reeds which he normally collected from the 
swamps. The proceeds from the sale of the mats was 
his additional family income. On examinations, he 
was in good general condition with a large ulcer in 
the upper right thigh, measuring over 25 centimetres 
in the longest diameter and was covering the anterior 
and medial portions. The wound was painless, was 
not causing him fever, the inguinal lymph nodes were 
not enlarged. The ulcer had undermining edges and 
the base was not fixed to the underlying structures 
and was not tender. The floor of the ulcer was dirty 
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with some scabs and debris ( Figure 1). 
 Swabs were taken from the floor and edges of 
the ulcer. One was used for microscopy. Gram stain 
was performed for general bacterial infections while 
the Zhiel Neelsen (ZN) was performed specifically for 
the Acid Alcohol Fast (AAFB) mycobacterium. The 
other swabs were used for culture both for general 
bacteria on Blood agar and MacConkey agar while 
the third swab was inoculated on Lowenstein Jensen 
medium for mycobacteria. Both Gram and ZN stains 
revealed no mycobacterium. However the culture 
results revealed the presence of mycobacterium 
ulcerans. Similarly, biopsy of the ulcer edges was 
done and the histology result was comparable with 
the culture results.
Treatment: The patient was started on rifampicin and 
streptomycin for eight weeks and after three weeks 
of treatment, the ulcer was skin grafted and the 
rehabilitation process successfully conducted and 
patient discharged healed physically in ten weeks.
DISCUSSION
The true incidence of Buruli ulcers is not well known 
and although it was first described in Uganda, in 
the sixties, it had literally been eradicated out from 
the country. This case is particularly unique and the 
fact that it is a rare occurrence in this particular area 
in Uganda (1-3). M. ulcerans is an environmental 
mycobacterium. Recent information suggests that the 
organism does not live freely in the environment, as 
previously thought, but is likely to occupy a specific 
niche within aquatic environments (for example small 
aquatic animals, biofilms) from where it is transmitted 
to humans by an unknown mechanism(9). Although 
slow growing, M. ulcerans can be cultured from 
human lesions on Lowenstein Jensen medium for 
mycobacteria, at incubation temperature between 
29–33°C. M. ulcerans produces a destructive toxin, 
mycolactone, which causes tissue damage and inhibits 
the immune response. The toxic effects of mycolactone 
explain most of the virulence of this organism (9, 
10). The exact mode of transmission is still under 
investigation. Some patients state that lesions develop 
at the site of antecedent trauma (10). Research in 
Africa suggests that, some aquatic insects of the 
order Hemiptera (Naucoridae and Belostomatidae) 
can harbour M. ulcerans in their salivary glands and 
transmit the disease to experimental animals (9,10). 
More recent data from Australia suggest that salt 
marsh mosquitoes test positive for M. ulcerans DNA, 
although transmission by this type of mosquito has 
not been established(9). Further research is in progress 
to establish the exact role of insects and other factors 
in the transmission of the disease to humans. Buruli 
ulcer frequently occurs near water bodies – slow 
flowing rivers, ponds, swamps and lakes; cases have 
also occurred following flooding (9,10). Exposure 
risk factors of economic and social activities that 
take place near water bodies are the major source of 
infections. The reasons for the growing spread of BU 
remain unclear. All ages and sexes are affected, but 
most patients are among children under 15 years. 
In general, there is no difference in the infection rate 
among males and females. The disease can affect any 
part of the body, but in about 90% of cases the lesions 
are on the limbs, with nearly 60% of all lesions on 
the lower limbs. There is also no evidence that the 
disease can be transmitted from person to person 
(9, 10). Buruli ulcer has been reported from many 
countries in tropical and subtropical regions. In Côte 
d’Ivoire 24,000 cases recorded between 1978–2006 (9). 
In Benin, 7,000 cases recorded between 1989-2006; 
in Ghana more than 11,000 recorded since 1993. In 
Australia, more cases of BU are being reported 25 in 
2004, 47 in 2005 and 72 in 2006. Most of the recent 
cases have come from the State of Victoria and the 
town of Point Lonsdale. Increasing number are 
being reported from West Africa and Uganda (9).
Some patients have been reported from China, but 
the extent of the disease is not known (9,10). Recent 
reports suggest, for the first time, that Brazil may be 
endemic in the areas bordering French Guyana (10). 
These numbers may only be an indication of the 
presence of the disease but not the magnitude of the 
problem. For these and other reasons, it is difficult to 
establish the exact number of people affected by the 
disease and the size and location of all endemic areas 
(10). BU often starts as a painless, mobile swelling in 
the skin called a nodule. The disease can present as 
a large area of induration or a diffuse swelling in the 
legs and arms (9,10). Strains of M. ulcerans isolated 
from the different clinical forms of the disease in 
a particular geographical region appear identical, 
suggesting that host factors may play an important 
role in determining the different clinical presentations. 
Because of the local immunosuppressive properties 
of mycolactone, or perhaps as a result of other 
unknown mechanisms, the disease progresses with 
no pain and fever, which may partly explain why 
those affected often, do not seek prompt treatment. 
However, without treatment, massive ulcers result, 
with the classical, undermined edges. Sometimes 
bone is affected causing gross deformities. When 
lesions heal, scarring may cause restricted movement 
of limbs and other permanent disabilities in about a 
quarter of patients (10). 
In Uganda, socio-cultural beliefs and practices 
strongly influence the health-seeking behaviours 
of people affected by BU. The first recourse is often 
traditional treatment. In addition to the high cost 
of surgical treatment, fear of surgery and concerns 
about the resulting scars and possible amputations 
may also prevail (1-5). Disfiguration stigma is a 
problem that also prevents people from seeking 
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early treatment. The long hospital stay, huge losses in 
productivity for adult patients which affects children 
educational opportunities. Bacille Calmette–Guérin 
(BCG) vaccination appears to offer some short-term 
protection from the disease although the protection 
is limited. Improved BCG-based vaccines, rational 
attenuation of a live M. ulcerans isolate or sub-unit 
vaccines, based on surface proteins or the toxin itself, 
are potential avenues for vaccine research. A safe 
and effective vaccine that can be targeted to newly 
emerging endemic areas may be the most effective 
way to combat BU in the long term (6-8).
Figure 1
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